Urogen Pharma (NASDAQ:URGN) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Urogen Pharma (NASDAQ:URGN) have earned an average rating of “Moderate Buy” from the eight ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $33.2857.

A number of research firms have recently commented on URGN. Oppenheimer restated an “outperform” rating on shares of Urogen Pharma in a research report on Monday, March 2nd. D. Boral Capital reaffirmed a “buy” rating and set a $33.00 target price on shares of Urogen Pharma in a report on Monday, March 2nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research note on Wednesday, January 21st.

Urogen Pharma Stock Performance

NASDAQ:URGN opened at $18.12 on Thursday. The business’s fifty day moving average is $19.94 and its 200 day moving average is $20.81. The firm has a market cap of $882.08 million, a price-to-earnings ratio of -5.66 and a beta of 1.34. Urogen Pharma has a 52-week low of $3.42 and a 52-week high of $30.00.

Urogen Pharma (NASDAQ:URGN) last issued its earnings results on Monday, March 2nd. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.12. The company had revenue of $37.84 million during the quarter, compared to the consensus estimate of $39.92 million. Equities analysts predict that Urogen Pharma will post -3.12 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, General Counsel Jason Drew Smith sold 7,479 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total transaction of $147,261.51. Following the completion of the transaction, the general counsel directly owned 51,326 shares in the company, valued at $1,010,608.94. The trade was a 12.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mark Schoenberg sold 7,373 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total value of $145,174.37. Following the transaction, the insider owned 144,985 shares of the company’s stock, valued at approximately $2,854,754.65. The trade was a 4.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 4.70% of the stock is owned by insiders.

Institutional Trading of Urogen Pharma

A number of large investors have recently modified their holdings of URGN. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Urogen Pharma by 27.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock worth $53,000 after purchasing an additional 486 shares during the last quarter. State of Wyoming purchased a new stake in Urogen Pharma in the third quarter valued at approximately $66,000. Russell Investments Group Ltd. lifted its position in Urogen Pharma by 1,594.4% during the third quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock valued at $66,000 after purchasing an additional 3,125 shares during the last quarter. Osaic Holdings Inc. lifted its position in Urogen Pharma by 491.2% during the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after purchasing an additional 3,070 shares during the last quarter. Finally, Strs Ohio purchased a new position in Urogen Pharma in the 3rd quarter worth approximately $76,000. Institutional investors own 91.29% of the company’s stock.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.